biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Post by Sinbobon Jun 11, 2012 8:22pm

346 Views

Post# 20001555

The immediate monstor in the room....

at this point in time would be the Shire licensing potential. Anyone's guess here is up for grabs. If I were the CEO of Shire today, I would be making some very urgent decisions that could affect that company for the next 20 years. Having the first options on a licensing agreement holds gravitas. Quick decisions must be made. In the Pharma world, he who hesitates is lost...and can be lost forever.

Then there are the 'other 50' Pharmas, some with over 7 1/2 billion shares out at $50 to $100/share. $500 million to $1 billion for many of them is peanuts....and they can finance it at about 2% with petty cash.

Bullboard Posts

Rig Count Soars as Utilization Surpasses Industry Averages